Adam Marc Apton
Levi & Korsinsky, LLP
- Address of record
- 33 Whitehall Street, 17th Floor, New York, NY 10004, 212-363-7500
- aapton@zlk.com
- Phone
- (212) 363-7500
Contact details as filed with the court in the cases below.
Case history
Publicly tracked matters where this attorney is listed as counsel.
PayPal Consumer Fraud Class Action
A proposed class action against PayPal Holdings Inc, apparently concerning fraud allegations. The court recently granted a motion to dismiss and gave the plaintiff leave to file an amended complaint. These allegations are not proven facts.
- Filed
- June 10, 2025
- Represents
- Caleb Brackney, Abigail Roskind, Jordan Leturgez, Annabelle Cruz, Annabelle Regan, Lily Fitzgerald, Ian Crowley, Antonio Minichiello, Alicia Freeman, Nicholas McDonald, Michael Amenti
PayPal Fraud Class Action
A proposed class action against PayPal, Inc., apparently concerning fraud. The case was filed under the 'Other Fraud' nature-of-suit code, which generally indicates claims of deceptive or fraudulent conduct. No further details are available from the caption or docket text.
- Filed
- April 1, 2025
- Represents
- Lily Fitzgerald, Ian Crowley, Antonio Minichiello, Alicia Freeman, Annabelle Regan, Nicholas McDonald, Michael Amenti, Caleb Brackney, Abigail Roskind, Jordan Leturgez, Annabelle Cruz
Sullivan Entertainment Class Action
A proposed class action has been filed against Sullivan Entertainment Inc. The available docket metadata does not describe the specific allegations, but the case is categorized as an 'Other Statutory Actions' matter. The plaintiff appears to seek relief on behalf of a class of individuals allegedly affected by the defendant's conduct under a federal statute.
- Filed
- March 26, 2025
- Represents
- Mark Glinoga
Harris Pharmaceutical Fraud Class Action
A proposed class action against Harris Pharmaceutical, Inc., apparently concerning fraud. The nature of suit is listed as 'Other Fraud,' but the docket text is unavailable, so specific factual allegations cannot be described. These are allegations in a newly filed case, not proven facts and not yet a settlement.
- Filed
- June 25, 2024
- Represents
- Laura Willis Albrigo
Masimo Securities Settlement
Masimo Corporation allegedly made misleading statements or omissions regarding its publicly traded common stock. Shareholders claim they were damaged by purchasing or acquiring the stock during the class period.
- Claim deadline
- April 28, 2026
- Represents
- Sergio Vazquez
Proterra Inc. Securities Litigation Settlement
Proterra Inc. and its defendants are settling securities litigation brought by shareholders who claim they were harmed by alleged misconduct related to Proterra's business combination with ArcLight Clean Transition Corp. and subsequent stock sales. The defendants are paying $29 million to resolve all claims without admitting wrongdoing.
- Settlement fund
- $29M
- Claim deadline
- August 29, 2025
- Represents
- Jeremy Villanueva, Tanya Tirado, William E. Zinn, Raymond H. Quick, Cyress Jam, Luong Du
ImmunityBio Inc. Securities Litigation Settlement
Lead Plaintiff alleges that ImmunityBio, Inc. and its executives made false or misleading statements regarding the company's securities during the class period. The defendants have agreed to settle the litigation for $10,500,000 in cash without admitting wrongdoing.
- Settlement fund
- $10.5M
- Claim deadline
- July 7, 2025
- Represents
- Timothy L. Van Eman
Olaplex Securities Settlement
Olaplex is settling a securities class action lawsuit alleging that the company made misrepresentations in its initial public offering documents. The defendant does not admit wrongdoing.
- Claim deadline
- November 24, 2025
- Represents
- Sara Wilson
Arqit Quantum Inc. Securities Settlement
Arqit Quantum Inc. (formerly Centricus Acquisition Corp.) and its executives allegedly made false or misleading statements and omissions regarding the company in connection with a merger and the offering of securities to investors. Defendants deny all wrongdoing and liability.
- Settlement fund
- $7M
- Claim deadline
- June 22, 2026
- Represents
- Erwin Jay Lack, Patrick L. Hagemeister
Katapult Securities Litigation Settlement
Defendants allegedly violated federal securities laws by making materially false and misleading statements regarding Katapult's financial prospects, causing the stock price to be artificially inflated. Additionally, FinServ failed to disclose critical information in its proxy statement regarding the business combination with Katapult. Defendants deny no wrongdoing is not stated, but the parties settled.
- Settlement fund
- $2.5M
- Claim deadline
- Represents
- Devang Patel
FibroGen, Inc. Securities Litigation Settlement
FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.
- Settlement fund
- $28.5M
- Claim deadline
- Represents
- George Assad
Tricida Securities Settlement
Tricida, Inc. and defendant Gerrit Klaerner are alleged to have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The defendant denies all claims and wrongdoing. The settlement resolves these allegations without admission of liability.
- Settlement fund
- $14.3M
- Claim deadline
- October 1, 2025
- Represents
- Nancy Catherine Wang
Turquoise Hill Resources Ltd. Securities Litigation Settlement
Rio Tinto plc, Rio Tinto Limited, and two executives made material misrepresentations and omissions about Turquoise Hill Resources' business, including misstatements about the development of the Oyu Tolgoi mine in Mongolia and related delays and cost overruns. Rio Tinto agreed to settle for $138.75 million without admitting wrongdoing.
- Settlement fund
- $138.8M
- Claim deadline
- September 24, 2025
- Represents
- Chang Pin Lin
Snap Inc. Securities Litigation Settlement
Plaintiffs alleged that Snap Inc., certain of its executives and directors, and underwriters for Snap's Initial Public Offering made materially false and misleading statements and omissions about Snap's business. The parties have reached proposed settlements to resolve these claims.
- Claim deadline
- Represents
- Sharmilli Ghosh
GM Engine Litigation Settlement
General Motors sold 2011-2014 Chevrolet and GMC pickup trucks and SUVs with LC9 5.3-liter V8 engines that allegedly contain a defective piston assembly. The defect causes excessive engine wear, oil consumption, spark plug fouling, rough idling, check engine lights, and potential engine damage. GM denies any wrongdoing or that the vehicles are defective.
- Settlement fund
- $150M
- Claim deadline
- Represents
- Adam Apton
Wilhite v. Expensify Securities Settlement
Expensify, Inc. and underwriter defendants allegedly made misrepresentations and omissions of material fact in Expensify's registration statement filed in connection with its November 10, 2021 initial public offering. Defendants admit no wrongdoing but agreed to settle to avoid the costs and uncertainties of further litigation.
- Settlement fund
- $9.5M
Rain Oncology Securities Settlement
Rain Oncology and its executives allegedly made misrepresentations and omissions about the company's development and commercialization of milademetan between April 2021 and May 2023. The defendants violated federal securities laws by making false or misleading statements in public filings. The defendants deny any wrongdoing.
- Settlement fund
- $7.3M
“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.